Advertisement

Drugs & Therapy Perspectives

, Volume 34, Issue 5, pp 203–206 | Cite as

Consider using opioids to treat restless legs syndrome in patients who have become refractory or intolerant to other treatments

  • Adis Medical Writers
Disease Management
  • 42 Downloads

Abstract

Although initially effective in treating restless legs syndrome (RLS), some treatments, such as dopamine agonists, eventually lose efficacy and may worsen RLS symptoms. According to current evidence, opioids are effective, and may be an appropriate option for treating patients with refractory RLS or those who cannot tolerant other treatments, given that the potential risk factors involved are carefully considered.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from Drugs 2017;77(12):1337-44 [1] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Mackie SE, Winkelman JW. Therapeutic utility of opioids for restless legs syndrome. Drugs. 2017;77(12):1337–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Adis Medical Writers. Adjust therapy for restless legs syndrome if symptoms worsen, efficacy is lost or iatrogenic augmentation develops. Drugs Ther Perspect. 2015;31(12):433–6.CrossRefGoogle Scholar
  4. 4.
    Tzonova D, Larrosa O, Calvo E, et al. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease). Sleep Med. 2012;13(2):151–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13(10):1280–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014;83(14):1277–84.CrossRefPubMedGoogle Scholar
  7. 7.
    von Spiczak S, Whone AL, Hammers A, et al. The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain. 2005;128(Pt 4):906–17.CrossRefGoogle Scholar
  8. 8.
    Mackie SE, McHugh RK, McDermott K, et al. Prevalence of restless legs syndrome during detoxification from alcohol and opioids. J Subst Abuse Treat. 2017;73:35–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Trzepacz PT, Violette EJ, Sateia MJ. Response to opioids in three patients with restless legs syndrome. Am J Psychiatry. 1984;141(8):993–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Hening WA, Walters A, Kavey N, et al. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology. 1986;36(10):1363–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16(4):327–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Trenkwalder C, Benes H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12(12):1141–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20(3):345–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Silver N, Allen RP, Senerth J, et al. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12(5):440–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord. 2001;16(6):1105–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585–93.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Chokroverty S. Opioid-induced hyperalgesia and dopamine-induced augmentation in an intractable and refractory case of RLS. Sleep Med. 2015;16(10):1304.  https://doi.org/10.1016/j.sleep.2015.08.005.CrossRefPubMedGoogle Scholar
  19. 19.
    Vetrugno R, La Morgia C, D’Angelo R, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007;22(3):424–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Rose AR, Catcheside PG, McEvoy RD, et al. Sleep disordered breathing and chronic respiratory failure in patients with chronic pain on long term opioid therapy. J Clin Sleep Med. 2014;10(8):847–52.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations